The Changing IP Landscape: Biopharma is the Battleground for Supreme Court Patent Assault
Executive Summary
The Supreme Court previously took a hands-off approach to IP cases, often going whole terms without deciding matters in this area, but that era appears to be coming to an end. The current justices have shown a renewed interest in patents, handing down one or more major decisions in each of the past few years. The life science industry will not only be affected by this shift; it is largely the means through which the Supreme Court is engineering this change in direction, particularly in the biopharma industry.
You may also be interested in...
Invalid! The Supreme Court Questions the Basis for Diagnostic Patents
The Supreme Court has decided to hear a case--LabCorp. vs Metabolite--that could invalidate patents based on the correlation between natural biological markers, like proteins or genes, and a disease. The case strikes at the heart of the new diagnostics start-ups-and could also invalidate a host of pharmaceutical IP strategies.
Supreme Court Puts Tools in Turmoil
In a blow for tool companies and a boost for drug developers, the Supreme Court in June held that drug companies could--in specific circumstances--use tool patents without paying for them. The problem: no one knows just how much protection the ruling affords. Even drug-developing biotechs, who now get a freer hand with other companies' tools, aren't universally happy with the ruling.
Pharma Blames EU IVD Regulation For Clinical Trial Delays
The challenges posed by the implementation of the EU IVD Regulation are having a negative impact on medicine trials using diagnostics. Many of such studies are currently stalled and research-based drug companies are calling on all partners to engage in dialog to find an urgent solution.